CI
EBS icon

CX Institutional’s Emergent Biosolutions EBS Stock Holding History

CX Institutional’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,754
Closed -$438K – 489
2021
Q3 		$438K Buy
8,754
+318
+4% +$19.3K 0.04% 272
2021
Q2 		$531K Buy
+8,436
New +$542K 0.04% 242

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CX Institutional's EBS Position: Q4 2021 in Review

CX Institutional sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 8,754 shares — an estimated $438K sold.

CX Institutional first reported a position in EBS in Q2 2021 and held it in 2 quarters. The position peaked at $531K in Q2 2021. 254 funds tracked by Wall St. Rank hold EBS as of Q4 2021.

  • CX Institutional reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
  • CX Institutional sold 8,754 Emergent Biosolutions shares in Q4 2021, an estimated $438K.
  • CX Institutional first reported a position in Emergent Biosolutions in Q2 2021 and held it in 2 quarters.
  • CX Institutional's Emergent Biosolutions position peaked at $531K in Q2 2021.
  • 254 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.

Based on CX Institutional's 13F filing for Q4 2021, filed 18 Jan 2022.